I would think if a mid-tier company is doing a licensing deal they would want the upfront cash to be used only for the part of the license related to that indication. Also, mono is a long way off for approval (in theory) so finalizing a deal including mono is unlikely. What would be crazy is if later some deal for mono is done for the US market with a different company, and the licensee for the combo indication is basically left in the cold. What revenue from combo would there be if the same drug is on the market as a mono drug? I'm sure this has been thought out but it is an odd situation.